REDUCTION BY MEFENAMIC ACID OF INCREASED MENSTRUAL BLOOD LOSS ASSOCIATED WITH TNTRAUTERINE CONTRACEPTION
Article first published online: 23 AUG 2005
DOI: 10.1111/j.1471-0528.1978.tb15826.x
Issue
1471-0528/asset/cover.gif?v=1&s=b4e1d96c46e18c61210d584b63c13ee375cf562b)
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 85, Issue 1, pages 53–62, January 1978
Additional Information
How to Cite
Guillebaud, J., Anderson, A. B. M. and Turnbull, A. C. (1978), REDUCTION BY MEFENAMIC ACID OF INCREASED MENSTRUAL BLOOD LOSS ASSOCIATED WITH TNTRAUTERINE CONTRACEPTION. BJOG: An International Journal of Obstetrics & Gynaecology, 85: 53–62. doi: 10.1111/j.1471-0528.1978.tb15826.x
Publication History
- Issue published online: 23 AUG 2005
- Article first published online: 23 AUG 2005
- Abstract
- References
- Cited By
Summary
Twenty-five healthy parous women using intrauterine contraceptive devices (IUCD's) received mefenamic acid, 500 mg 8-hourly, during two menstrual periods. Two pre- and two post-treatment menses were similarly studied, by the collection of used sanitary pads and/or tampons and measurement of daily blood loss. A highly significant reduction in mean total blood loss during the treatment periods was observed, unaffected by whether therapy began on the first day of bleeding or in the late luteal phase. The reduction was observed among both inert and copper-containing IUCD-users. Expressed as a percentage of the mean pre-treatment volume, the reduction in loss was not significantly different for those IUCD-users who were light losers (less than 80 ml) compared with heavy losers (80 ml or more), but it was greater in volume terms among the latter. The amounts lost during the post-treatment periods, whether or not placebo tablets were given, were not significantly different from pre-treatment. Reports of side effects were infrequent. By contrast with the reduction in volume lost, no effect of mefenamic acid on the total duration of bleeding and non-collectable 'spotting’could be demonstrated.

1471-0528/asset/BJO_left.gif?v=1&s=0fb87361cdb6be25fdf05019eed6d47f5143f610)
1471-0528/asset/olbannerright.gif?v=1&s=3892ef16ff18d6834c302faf85268a49f5fc588f)